Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar for Cardiovascular Risk Reduction in Stable Cardiovascular Disease with Glucose Abnormalities
2012-000671-16Phase 3Terminated
- Sponsor
- Roche
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, type 2 diabetes mellitus (T2DM) and dysglycemia comparing Aleglitazar with Placebo (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Started Aug 2012; status: terminated.
02
Drugs
aleglitazar
03
Conditions
cardiac morbiditytype 2 diabetes mellitus (T2DM)dysglycemia
Beyond the preview
Go deeper on 2012-000671-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000671-16.